|
1
|
Duffy MJ and O'Byrne K: Tissue and blood
biomarkers in lung cancer: A review. Adv Clin Chem. 86:1–21. 2018.
View Article : Google Scholar
|
|
2
|
Khan M, Lin J, Liao G, Tian Y, Liang Y, Li
R, Liu M and Yuan Y: ALK inhibitors in the treatment of ALK
positive NSCLC. Front Oncol. 8:5572019. View Article : Google Scholar
|
|
3
|
Melosky B, Cheema P, Agulnik J, Albadine
R, Bebb DG, Blais N, Burkes R, Butts C, Card PB, Chan AMY, et al:
Canadian perspectives: Update on inhibition of ALK-positive tumours
in advanced non-small-cell lung cancer. Curr Oncol. 25:317–328.
2018. View Article : Google Scholar
|
|
4
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar
|
|
5
|
Chan BA and Hughes BG: Targeted therapy
for non-small cell lung cancer: Current standards and the promise
of the future. Transl Lung Cancer Res. 4:36–54. 2015.
|
|
6
|
D'Arcangelo M, Wynes MW and Hirsch FR: The
role of anaplastic lymphoma kinase inhibitors in the treatment of
advanced nonsmall cell lung cancer. Curr Opin Oncol. 25:121–129.
2013. View Article : Google Scholar
|
|
7
|
Huang H: Anaplastic lymphoma kinase (ALK)
receptor tyrosine kinase: A catalytic receptor with many faces. Int
J Mol Sci. 19:34482018. View Article : Google Scholar
|
|
8
|
Golding B, Luu A, Jones R and
Viloria-Petit AM: The function and therapeutic targeting of
anaplastic lymphoma kinase (ALK) in non-small cell lung cancer
(NSCLC). Mol Cancer. 17:522018. View Article : Google Scholar
|
|
9
|
Roskoski R Jr: Anaplastic lymphoma kinase
(ALK) inhibitors in the treatment of ALK-driven lung cancers.
Pharmacol Res. 117:343–356. 2017. View Article : Google Scholar
|
|
10
|
Zhang Z, Guo H, Lu Y, Hao W and Han L:
Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer
patients with brain metastases: A meta-analysis. J Thorac Dis.
11:1397–1409. 2019. View Article : Google Scholar
|
|
11
|
Sgambato A, Casaluce F, Maione P and
Gridelli C: Targeted therapies in non-small cell lung cancer: A
focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer
Ther. 18:71–80. 2018. View Article : Google Scholar
|
|
12
|
Cui S, Zhao Y, Gu A, Ge X, Song Y, Zhang
W, Lou Y, Dong L, Han B and Jiang L: Efficacy and tolerability of
crizotinib in the treatment of ALK-positive, advanced non-small
cell lung cancer in Chinese patients. Med Oncol. 32:6262015.
View Article : Google Scholar
|
|
13
|
Califano R, Greystoke A, Lal R, Thompson J
and Popat S: Management of ceritinib therapy and adverse events in
patients with ALK-rearranged non-small cell lung cancer. Lung
Cancer. 111:51–58. 2017. View Article : Google Scholar
|
|
14
|
Zhu V and Ou SH: Safety of alectinib for
the treatment of metastatic ALK-rearranged non-small cell lung
cancer. Expert Opin Drug Saf. 16:509–514. 2017. View Article : Google Scholar
|
|
15
|
Sabari JK, Santini FC, Schram AM,
Bergagnini I, Chen R, Mrad C, Lai WV, Arbour KC and Drilon A: The
activity, safety, and evolving role of brigatinib in patients with
ALK-rearranged non-small cell lung cancers. Onco Targets Ther.
10:1983–1992. 2017. View Article : Google Scholar
|
|
16
|
Bauer TM, Felip E, Solomon BJ, Thurm H,
Peltz G, Chioda MD and Shaw AT: Clinical management of adverse
events associated with lorlatinib. Oncologist. 24:1103–1110. 2019.
View Article : Google Scholar
|
|
17
|
Spagnuolo A, Maione P and Gridelli C:
Evolution in the treatment landscape of non-small cell lung cancer
with ALK gene alterations: From the first- to third-generation of
ALK inhibitors. Expert Opin Emerg Drugs. 23:231–241. 2018.
View Article : Google Scholar
|
|
18
|
Gadgeel SM: The use of alectinib in the
first-line treatment of anaplastic lymphoma kinase-positive
non-small-cell lung cancer. Future Oncol. 14:1875–1882. 2018.
View Article : Google Scholar
|
|
19
|
Vavala T and Novello S: Alectinib in the
treatment of ALK-positive non-small cell lung cancer: An update on
its properties, efficacy, safety and place in therapy. Ther Adv Med
Oncol. 10:17588359187893642018. View Article : Google Scholar
|
|
20
|
Paik J and Dhillon S: Alectinib: A review
in advanced, ALK-positive NSCLC. Drugs. 78:1247–1257. 2018.
View Article : Google Scholar
|
|
21
|
Cortinovis D, Canova S, Abbate MI,
Colonese F, Cogliati V and Bidoli P: Challenges in ALK inhibition
of ALK-positive non-small-cell lung cancer: From ALK positivity
detection to treatment strategies after relapse. Future Oncol.
14:2303–2317. 2018. View Article : Google Scholar
|
|
22
|
Peters S and Zimmermann S: Management of
resistance to first-line anaplastic lymphoma kinase tyrosine kinase
inhibitor therapy. Curr Treat Options Oncol. 19:372018. View Article : Google Scholar
|
|
23
|
Dagogo-Jack I and Shaw AT: Crizotinib
resistance: Implications for therapeutic strategies. Ann Oncol. 27
(Suppl 3):iii42–iii50. 2016. View Article : Google Scholar
|
|
24
|
Ali R, Arshad J, Palacio S and Mudad R:
Brigatinib for ALK-positive metastatic non-small-cell lung cancer:
Design, development and place in therapy. Drug Des Devel Ther.
13:569–580. 2019. View Article : Google Scholar
|
|
25
|
Bedi S, Khan SA, AbuKhader MM, Alam P,
Siddiqui NA and Husain A: A comprehensive review on Brigatinib-A
wonder drug for targeted cancer therapy in non-small cell lung
cancer. Saudi Pharm J. 26:755–763. 2018. View Article : Google Scholar
|
|
26
|
Pfizer Inc.: XALKORI 2011, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202570s028lbl.pdfJanuary
10–2019
|
|
27
|
Xu H, O'Gorman M, Boutros T, Brega N,
Kantaridis C, Tan W and Bello A: Evaluation of crizotinib absolute
bioavailability, the bioequivalence of three oral formulations, and
the effect of food on crizotinib pharmacokinetics in healthy
subjects. J Clin Pharmacol. 55:104–113. 2015. View Article : Google Scholar
|
|
28
|
Hamilton G, Rath B and Burghuber O:
Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug
Metab Toxicol. 11:835–842. 2015. View Article : Google Scholar
|
|
29
|
Fujiwara Y, Hamada A, Mizugaki H, Aikawa
H, Hata T, Horinouchi H, Kanda S, Goto Y, Itahashi K, Nokihara H,
et al: Pharmacokinetic profiles of significant adverse events with
crizotinib in Japanese patients with ABCB1 polymorphism. Cancer
Sci. 107:1117–1123. 2016. View Article : Google Scholar
|
|
30
|
El-Khoueiry AB, Sarantopoulos J, O'Bryant
CL, Ciombor KK, Xu H, O'Gorman M, Chakrabarti J, Usari T and
El-Rayes BF: Evaluation of hepatic impairment on pharmacokinetics
and safety of crizotinib in patients with advanced cancer. Cancer
Chemother Pharmacol. 81:659–670. 2018. View Article : Google Scholar
|
|
31
|
Tan W, Yamazaki S, Johnson TR, Wang R,
O'Gorman MT, Kirkovsky L, Boutros T, Brega NM and Bello A: Effects
of renal function on crizotinib pharmacokinetics: Dose
recommendations for patients with ALK-positive non-small cell lung
cancer. Clin Drug Investig. 37:363–373. 2017. View Article : Google Scholar
|
|
32
|
Hirota T, Muraki S and Ieiri I: Clinical
pharmacokinetics of anaplastic lymphoma kinase inhibitors in
non-small-cell lung cancer. Clin Pharmacokinet. 58:403–420. 2019.
View Article : Google Scholar
|
|
33
|
Pirker R and Filipits M: From crizotinib
to lorlatinib: Continuous improvement in precision treatment of
ALK-positive non-small cell lung cancer. ESMO Open. 4:e0005482019.
View Article : Google Scholar
|
|
34
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar
|
|
35
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar
|
|
36
|
Nishio M, Kim DW, Wu YL, Nakagawa K,
Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, et
al: Crizotinib versus chemotherapy in asian patients with
ALK-positive advanced non-small cell lung cancer. Cancer Res Treat.
50:691–700. 2018. View Article : Google Scholar
|
|
37
|
Deeks ED: Ceritinib: A review in
ALK-positive advanced NSCLC. Target Oncol. 11:693–700. 2016.
View Article : Google Scholar
|
|
38
|
Tomasini P, Egea J, Souquet-Bressand M,
Greillier L and Barlesi F: Alectinib in the treatment of
ALK-positive metastatic non-small cell lung cancer: Clinical trial
evidence and experience with a focus on brain metastases. Ther Adv
Respir Dis. 13:17534666198319062019. View Article : Google Scholar
|
|
39
|
Claxton L, O'Connor J, Woolacott N, Wright
K and Hodgson R: Ceritinib for untreated anaplastic lymphoma
kinase-positive advanced non-small-cell lung cancer: An evidence
review group evaluation of a NICE single technology appraisal.
Pharmacoeconomics. 37:645–654. 2019. View Article : Google Scholar
|
|
40
|
Friboulet L, Li N, Katayama R, Lee CC,
Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S,
et al: The ALK inhibitor ceritinib overcomes crizotinib resistance
in non-small cell lung cancer. Cancer Discov. 4:662–673. 2014.
View Article : Google Scholar
|
|
41
|
Shaw AT, Kim DW, Mehra R, Tan DS, Felip E,
Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, et al:
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J
Med. 370:1189–1197. 2014. View Article : Google Scholar
|
|
42
|
Gainor JF and Shaw AT: Fast, food and
ceritinib in ALK-positive NSCLC. J Thorac Oncol. 12:1341–1343.
2017. View Article : Google Scholar
|
|
43
|
Soria JC, Tan DSW, Chiari R, Wu YL,
Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, et al:
First-line ceritinib versus platinum-based chemotherapy in advanced
ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised,
open-label, phase 3 study. Lancet. 389:917–929. 2017. View Article : Google Scholar
|
|
44
|
Shaw AT, Kim TM, Crinò L, Gridelli C,
Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, et al:
Ceritinib versus chemotherapy in patients with ALK-rearranged
non-small-cell lung cancer previously given chemotherapy and
crizotinib (ASCEND-5): A randomised, controlled, open-label, phase
3 trial. Lancet Oncol. 18:874–886. 2017. View Article : Google Scholar
|
|
45
|
Beardslee T and Lawson J: Alectinib and
brigatinib: New second-generation ALK inhibitors for the treatment
of non-small cell lung cancer. J Adv Pract Oncol. 9:94–101.
2018.
|
|
46
|
Parrott NJ, Yu LJ, Takano R, Nakamura M
and Morcos PN: Physiologically based absorption modeling to explore
the impact of food and gastric pH changes on the pharmacokinetics
of alectinib. AAPS J. 18:1464–1474. 2016. View Article : Google Scholar
|
|
47
|
Novello S, Mazieres J, Oh IJ, de Castro J,
Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A,
Zeaiter A, et al: Alectinib versus chemotherapy in
crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive
non-small-cell lung cancer: Results from the phase III ALUR study.
Ann Oncol. 29:1409–1416. 2018. View Article : Google Scholar
|
|
48
|
Hida T, Nokihara H, Kondo M, Kim YH, Azuma
K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, et al:
Alectinib versus crizotinib in patients with ALK-positive
non-small-cell lung cancer (J-ALEX): An open-label, randomised
phase 3 trial. Lancet. 390:29–39. 2017. View Article : Google Scholar
|
|
49
|
Peters S, Camidge DR, Shaw AT, Gadgeel S,
Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, et al:
Alectinib versus crizotinib in untreated ALK-positive
non-small-cell lung cancer. N Engl J Med. 377:829–838. 2017.
View Article : Google Scholar
|
|
50
|
Umbela S, Ghacha S, Matuknauth R, Gause S,
Joshee S and Deshmukh RR: Brigatinib: New-generation ALK inhibitor
for nonsmall cell lung cancer. Curr Probl Cancer. 43:1004772019.
View Article : Google Scholar
|
|
51
|
Markham A: Brigatinib: First global
approval. Drugs. 77:1131–1135. 2017. View Article : Google Scholar
|
|
52
|
Tugnait M, Gupta N, Hanley MJ, Sonnichsen
D, Kerstein D, Dorer DJ, Venkatakrishnan K and Narasimhan N:
Effects of strong CYP2C8 or CYP3A inhibition and CYP3A induction on
the pharmacokinetics of brigatinib, an oral anaplastic lymphoma
kinase inhibitor, in healthy volunteers. Clin Pharmacol Drug Dev.
9:214–223. 2020. View Article : Google Scholar
|
|
53
|
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han
JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, et al: Brigatinib
versus crizotinib in ALK-positive non-small-cell lung cancer. N
Engl J Med. 379:2027–2039. 2018. View Article : Google Scholar
|
|
54
|
Al-Salama ZT and Keam SJ: Entrectinib:
First global approval. Drugs. 79:1477–1483. 2019. View Article : Google Scholar
|
|
55
|
Genentech Inc: ROZLYTREK 2019. simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdfJanuary
10–2019
|
|
56
|
Wang Q, Fang P, Zheng L and Ye L:
Quantification and pharmacokinetic study of entrectinib in rat
plasma using ultra-performance liquid chromatography tandem mass
spectrometry. Biomed Chromatogr. 33:e44672019.
|
|
57
|
Liu D, Offin M, Harnicar S, Li BT and
Drilon A: Entrectinib: An orally available, selective tyrosine
kinase inhibitor for the treatment of NTRK, ROS1, and ALK
fusion-positive solid tumors. Ther Clin Risk Manag. 14:1247–1252.
2018. View Article : Google Scholar
|
|
58
|
Pfizer Inc: Lorbrena 2018. simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdfJanuary
10–2019
|
|
59
|
Akamine T, Toyokawa G, Tagawa T and Seto
T: Spotlight on lorlatinib and its potential in the treatment of
NSCLC: The evidence to date. Onco Targets Ther. 11:5093–5101. 2018.
View Article : Google Scholar
|
|
60
|
Li W, Sparidans RW, Wang Y, Lebre MC,
Wagenaar E, Beijnen JH and Schinkel AH: P-glycoprotein (MDR1/ABCB1)
restricts brain accumulation and cytochrome P450-3A (CYP3A) limits
oral availability of the novel ALK/ROS1 inhibitor lorlatinib. Int J
Cancer. 143:2029–2038. 2018. View Article : Google Scholar
|
|
61
|
Wu YL, Lu S, Lu Y, Zhou J, Shi YK,
Sriuranpong V, Ho JCM, Ong CK, Tsai CM, Chung CH, et al: Results of
PROFILE 1029, a phase III comparison of first-line crizotinib
versus chemotherapy in east asian patients with ALK-positive
advanced non-small cell lung cancer. J Thorac Oncol. 13:1539–1548.
2018. View Article : Google Scholar
|
|
62
|
Yoneda KY, Scranton JR, Cadogan MA,
Tassell V, Nadanaciva S, Wilner KD and Stollenwerk NS: Interstitial
lung disease associated with crizotinib in patients with advanced
non-small cell lung cancer: Independent review of four PROFILE
trials. Clin Lung Cancer. 18:472–479. 2017. View Article : Google Scholar
|
|
63
|
Shah RR, Morganroth J and Shah DR:
Hepatotoxicity of tyrosine kinase inhibitors: Clinical and
regulatory perspectives. Drug Saf. 36:491–503. 2013. View Article : Google Scholar
|
|
64
|
Liu B, Yuan M, Sun Y, Cheng Z, Zhang Z,
Hou S, Wang X and Liu J: Incidence and risk of hepatic toxicities
associated with anaplastic lymphoma kinase inhibitors in the
treatment of non-small-cell lung cancer: A systematic review and
meta-analysis. Oncotarget. 9:9480–9488. 2017. View Article : Google Scholar
|
|
65
|
Costa RB, Costa RLB, Talamantes SM, Kaplan
JB, Bhave MA, Rademaker A, Miller C, Carneiro BA, Mahalingam D and
Chae YK: Systematic review and meta-analysis of selected toxicities
of approved ALK inhibitors in metastatic non-small cell lung
cancer. Oncotarget. 9:22137–22146. 2018. View Article : Google Scholar
|
|
66
|
Zhu Q, Hu H, Weng DS, Zhang XF, Chen CL,
Zhou ZQ, Tang Y and Xia JC: Pooled safety analyses of ALK-TKI
inhibitor in ALK-positive NSCLC. BMC Cancer. 17:4122017. View Article : Google Scholar
|
|
67
|
Zhu VW, Lu Y and Ou SI: Severe acute
hepatitis in a patient receiving alectinib for ALK-positive
non-small-cell lung cancer: Histologic analysis. Clin Lung Cancer.
20:e77–e80. 2019. View Article : Google Scholar
|
|
68
|
Jung D, Han JM, Yee J, Kim JY and Gwak HS:
Factors affecting crizotinib-induced hepatotoxicity in non-small
cell lung cancer patients. Med Oncol. 35:1542018. View Article : Google Scholar
|
|
69
|
Van Sebille YZ, Gibson RJ, Wardill HR and
Bowen JM: ErbB small molecule tyrosine kinase inhibitor (TKI)
induced diarrhoea: Chloride secretion as a mechanistic hypothesis.
Cancer Treat Rev. 41:646–652. 2015. View Article : Google Scholar
|
|
70
|
Schaefer ES and Baik C: Proactive
management strategies for potential gastrointestinal adverse
reactions with ceritinib in patients with advanced ALK-positive
non-small-cell lung cancer. Cancer Manag Res. 8:33–38. 2016.
View Article : Google Scholar
|
|
71
|
Ariad, . ALUNBRIG. 2017. simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdfJanuary
10–2019
|
|
72
|
Pellegrino B, Facchinetti F, Bordi P,
Silva M, Gnetti L and Tiseo M: Lung toxicity in non-small-cell lung
cancer patients exposed to ALK inhibitors: Report of a peculiar
case and systematic review of the literature. Clin Lung Cancer.
19:e151–e161. 2018. View Article : Google Scholar
|
|
73
|
Gemma A, Kusumoto M, Kurihara Y, Masuda N,
Banno S, Endo Y, Houzawa H, Ueno N, Ohki E and Yoshimura A:
Interstitial lung disease onset and its risk factors in Japanese
patients with ALK-positive NSCLC after treatment with crizotinib. J
Thorac Oncol. 14:672–682. 2019. View Article : Google Scholar
|
|
74
|
Gettinger SN, Bazhenova LA, Langer CJ,
Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M,
Narasimhan NI, et al: Activity and safety of brigatinib in
ALK-rearranged non-small-cell lung cancer and other malignancies: A
single-arm, open-label, phase 1/2 trial. Lancet Oncol.
17:1683–1696. 2016. View Article : Google Scholar
|
|
75
|
Domenech M, Jove M, Aso S, Marin M and
Nadal E: Successful treatment with brigatinib in a patient with
ALK-rearranged lung adenocarcinoma who developed crizotinib-induced
interstitial lung disease. Lung Cancer. 119:99–102. 2018.
View Article : Google Scholar
|
|
76
|
Novartis Inc: Zykadia, . 2014, simplehttps://www.pharma.us.novartis.com/product/pi/pdf/zykadia.pdfJanuary
10–2019
|
|
77
|
Hoffmann-La Roche: ALECENSA. 2015.
simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdfJanuary
10–2019
|
|
78
|
Morcos PN, Bogman K, Hubeaux S,
Sturm-Pellanda C, Ruf T, Bordogna W, Golding S, Zeaiter A, Abt M
and Balas B: Effect of alectinib on cardiac electrophysiology:
Results from intensive electrocardiogram monitoring from the
pivotal phase II NP28761 and NP28673 studies. Cancer Chemother
Pharmacol. 79:559–568. 2017. View Article : Google Scholar
|
